NEW ENGLAND JOURNAL OF MEDICINE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1095591, encodeId=1d9510955911a, content=作者可以写中文名么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=541, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055215, encodeId=8c241055215ee, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：临床研究 经验分享：临床研究，2021-7-31投稿；8-1 Administrative Screening，期间格式修改一次耽误几天；8-5 searching for review； 8-8 out for review； 8-25 reject with comments 回来两个审稿人的意见，加起来很少，但是非常不友好，乱说一通，致命的是说对照组不是标准治疗，我们对照组用的方案在指南里面。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=850, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/29/c68ffa2138c126af3420089371aaee39.jpg, createdBy=b9481711950, createdName=文多多钱多多房多多, createdTime=Mon Sep 27 03:34:50 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887580, encodeId=67bb88e5802b, content=投个image试试水，目前with the editor,看了一下以往发表的文章，应该不符合编辑的口味，据说image拒稿率99%。大家加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=587, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Wed Sep 23 08:27:02 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923533, encodeId=449592353316, content=投了一篇letter不知道with edtor要多少天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Sun Feb 07 20:48:35 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519664, encodeId=68e35196644d, content=投了1篇病例报道，现在Assigned to an Editor，估计希望不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=906, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sat Feb 27 10:15:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114318, encodeId=a6a22114318b9, content=偏重的研究方向：临床研究;随机对照研究 经验分享：投了一篇评论的文章，已经一个多月with editor了，很快文章发表要满14天了，不知道是不是稿件统一处理，希望有好消息！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Mon Feb 13 00:16:54 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122324, encodeId=129721223244b, content=有幸被NEJM一审修回，请问一下修回之后一直显示Administrative Screening，这正常吗？这个状态一般持续多长时间？目前已经10天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07d18126736, createdName=ms3000001187334160, createdTime=Tue Mar 28 20:02:46 CST 2023, time=2023-03-28, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=486910, encodeId=6ccc486910a0, content=近来投了IMAGE IN CLINICAL MEDICINE,不知道结果怎么样，等吧~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1738, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Feb 24 18:02:00 CST 2012, time=2012-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183346, encodeId=65c9218334693, content=23.12.17投稿 picture，with the editor 一月有余, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9f5529296, createdName=ms6000000966266302, createdTime=Tue Jan 23 03:56:44 CST 2024, time=2024-01-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2129787, encodeId=22112129e8779, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床研究;临床医学;随机对照研究 经验分享：国内2023年在NEJM上有可能突破8篇article!2025年十篇以上，以后每年10篇以上，到2030年每年可以达20篇！事实上NEJM每年article也仅100篇多一点。<a href='/topic/show?id=4041126241e' target=_blank style='color:#2F92EE;'>#NEJM#</a><a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=12624, encryptionId=4041126241e, topicName=NEJM), TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed May 03 02:33:50 CST 2023, time=2023-05-03, status=1, ipAttribution=美国)]

2021-12-28 MS54455111222

作者可以写中文名么？

541 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1095591, encodeId=1d9510955911a, content=作者可以写中文名么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=541, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055215, encodeId=8c241055215ee, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：临床研究 经验分享：临床研究，2021-7-31投稿；8-1 Administrative Screening，期间格式修改一次耽误几天；8-5 searching for review； 8-8 out for review； 8-25 reject with comments 回来两个审稿人的意见，加起来很少，但是非常不友好，乱说一通，致命的是说对照组不是标准治疗，我们对照组用的方案在指南里面。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=850, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/29/c68ffa2138c126af3420089371aaee39.jpg, createdBy=b9481711950, createdName=文多多钱多多房多多, createdTime=Mon Sep 27 03:34:50 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887580, encodeId=67bb88e5802b, content=投个image试试水，目前with the editor,看了一下以往发表的文章，应该不符合编辑的口味，据说image拒稿率99%。大家加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=587, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Wed Sep 23 08:27:02 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923533, encodeId=449592353316, content=投了一篇letter不知道with edtor要多少天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Sun Feb 07 20:48:35 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519664, encodeId=68e35196644d, content=投了1篇病例报道，现在Assigned to an Editor，估计希望不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=906, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sat Feb 27 10:15:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114318, encodeId=a6a22114318b9, content=偏重的研究方向：临床研究;随机对照研究 经验分享：投了一篇评论的文章，已经一个多月with editor了，很快文章发表要满14天了，不知道是不是稿件统一处理，希望有好消息！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Mon Feb 13 00:16:54 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122324, encodeId=129721223244b, content=有幸被NEJM一审修回，请问一下修回之后一直显示Administrative Screening，这正常吗？这个状态一般持续多长时间？目前已经10天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07d18126736, createdName=ms3000001187334160, createdTime=Tue Mar 28 20:02:46 CST 2023, time=2023-03-28, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=486910, encodeId=6ccc486910a0, content=近来投了IMAGE IN CLINICAL MEDICINE,不知道结果怎么样，等吧~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1738, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Feb 24 18:02:00 CST 2012, time=2012-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183346, encodeId=65c9218334693, content=23.12.17投稿 picture，with the editor 一月有余, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9f5529296, createdName=ms6000000966266302, createdTime=Tue Jan 23 03:56:44 CST 2024, time=2024-01-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2129787, encodeId=22112129e8779, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床研究;临床医学;随机对照研究 经验分享：国内2023年在NEJM上有可能突破8篇article!2025年十篇以上，以后每年10篇以上，到2030年每年可以达20篇！事实上NEJM每年article也仅100篇多一点。<a href='/topic/show?id=4041126241e' target=_blank style='color:#2F92EE;'>#NEJM#</a><a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=12624, encryptionId=4041126241e, topicName=NEJM), TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed May 03 02:33:50 CST 2023, time=2023-05-03, status=1, ipAttribution=美国)]

2021-09-27 文多多钱多多房多多

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：临床研究
经验分享：临床研究，2021-7-31投稿；8-1 Administrative Screening，期间格式修改一次耽误几天；8-5 searching for review； 8-8 out for review； 8-25 reject with comments 回来两个审稿人的意见，加起来很少，但是非常不友好，乱说一通，致命的是说对照组不是标准治疗，我们对照组用的方案在指南里面。。。

850 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1095591, encodeId=1d9510955911a, content=作者可以写中文名么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=541, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055215, encodeId=8c241055215ee, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：临床研究 经验分享：临床研究，2021-7-31投稿；8-1 Administrative Screening，期间格式修改一次耽误几天；8-5 searching for review； 8-8 out for review； 8-25 reject with comments 回来两个审稿人的意见，加起来很少，但是非常不友好，乱说一通，致命的是说对照组不是标准治疗，我们对照组用的方案在指南里面。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=850, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/29/c68ffa2138c126af3420089371aaee39.jpg, createdBy=b9481711950, createdName=文多多钱多多房多多, createdTime=Mon Sep 27 03:34:50 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887580, encodeId=67bb88e5802b, content=投个image试试水，目前with the editor,看了一下以往发表的文章，应该不符合编辑的口味，据说image拒稿率99%。大家加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=587, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Wed Sep 23 08:27:02 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923533, encodeId=449592353316, content=投了一篇letter不知道with edtor要多少天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Sun Feb 07 20:48:35 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519664, encodeId=68e35196644d, content=投了1篇病例报道，现在Assigned to an Editor，估计希望不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=906, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sat Feb 27 10:15:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114318, encodeId=a6a22114318b9, content=偏重的研究方向：临床研究;随机对照研究 经验分享：投了一篇评论的文章，已经一个多月with editor了，很快文章发表要满14天了，不知道是不是稿件统一处理，希望有好消息！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Mon Feb 13 00:16:54 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122324, encodeId=129721223244b, content=有幸被NEJM一审修回，请问一下修回之后一直显示Administrative Screening，这正常吗？这个状态一般持续多长时间？目前已经10天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07d18126736, createdName=ms3000001187334160, createdTime=Tue Mar 28 20:02:46 CST 2023, time=2023-03-28, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=486910, encodeId=6ccc486910a0, content=近来投了IMAGE IN CLINICAL MEDICINE,不知道结果怎么样，等吧~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1738, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Feb 24 18:02:00 CST 2012, time=2012-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183346, encodeId=65c9218334693, content=23.12.17投稿 picture，with the editor 一月有余, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9f5529296, createdName=ms6000000966266302, createdTime=Tue Jan 23 03:56:44 CST 2024, time=2024-01-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2129787, encodeId=22112129e8779, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床研究;临床医学;随机对照研究 经验分享：国内2023年在NEJM上有可能突破8篇article!2025年十篇以上，以后每年10篇以上，到2030年每年可以达20篇！事实上NEJM每年article也仅100篇多一点。<a href='/topic/show?id=4041126241e' target=_blank style='color:#2F92EE;'>#NEJM#</a><a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=12624, encryptionId=4041126241e, topicName=NEJM), TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed May 03 02:33:50 CST 2023, time=2023-05-03, status=1, ipAttribution=美国)]

2020-09-23 1781f75bccm

投个image试试水，目前with the editor,看了一下以往发表的文章，应该不符合编辑的口味，据说image拒稿率99%。大家加油

587 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1095591, encodeId=1d9510955911a, content=作者可以写中文名么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=541, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055215, encodeId=8c241055215ee, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：临床研究 经验分享：临床研究，2021-7-31投稿；8-1 Administrative Screening，期间格式修改一次耽误几天；8-5 searching for review； 8-8 out for review； 8-25 reject with comments 回来两个审稿人的意见，加起来很少，但是非常不友好，乱说一通，致命的是说对照组不是标准治疗，我们对照组用的方案在指南里面。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=850, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/29/c68ffa2138c126af3420089371aaee39.jpg, createdBy=b9481711950, createdName=文多多钱多多房多多, createdTime=Mon Sep 27 03:34:50 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887580, encodeId=67bb88e5802b, content=投个image试试水，目前with the editor,看了一下以往发表的文章，应该不符合编辑的口味，据说image拒稿率99%。大家加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=587, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Wed Sep 23 08:27:02 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923533, encodeId=449592353316, content=投了一篇letter不知道with edtor要多少天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Sun Feb 07 20:48:35 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519664, encodeId=68e35196644d, content=投了1篇病例报道，现在Assigned to an Editor，估计希望不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=906, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sat Feb 27 10:15:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114318, encodeId=a6a22114318b9, content=偏重的研究方向：临床研究;随机对照研究 经验分享：投了一篇评论的文章，已经一个多月with editor了，很快文章发表要满14天了，不知道是不是稿件统一处理，希望有好消息！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Mon Feb 13 00:16:54 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122324, encodeId=129721223244b, content=有幸被NEJM一审修回，请问一下修回之后一直显示Administrative Screening，这正常吗？这个状态一般持续多长时间？目前已经10天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07d18126736, createdName=ms3000001187334160, createdTime=Tue Mar 28 20:02:46 CST 2023, time=2023-03-28, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=486910, encodeId=6ccc486910a0, content=近来投了IMAGE IN CLINICAL MEDICINE,不知道结果怎么样，等吧~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1738, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Feb 24 18:02:00 CST 2012, time=2012-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183346, encodeId=65c9218334693, content=23.12.17投稿 picture，with the editor 一月有余, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9f5529296, createdName=ms6000000966266302, createdTime=Tue Jan 23 03:56:44 CST 2024, time=2024-01-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2129787, encodeId=22112129e8779, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床研究;临床医学;随机对照研究 经验分享：国内2023年在NEJM上有可能突破8篇article!2025年十篇以上，以后每年10篇以上，到2030年每年可以达20篇！事实上NEJM每年article也仅100篇多一点。<a href='/topic/show?id=4041126241e' target=_blank style='color:#2F92EE;'>#NEJM#</a><a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=12624, encryptionId=4041126241e, topicName=NEJM), TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed May 03 02:33:50 CST 2023, time=2023-05-03, status=1, ipAttribution=美国)]

2021-02-07 12103978m50暂无昵称

投了一篇letter不知道with edtor要多少天

0 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1095591, encodeId=1d9510955911a, content=作者可以写中文名么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=541, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055215, encodeId=8c241055215ee, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：临床研究 经验分享：临床研究，2021-7-31投稿；8-1 Administrative Screening，期间格式修改一次耽误几天；8-5 searching for review； 8-8 out for review； 8-25 reject with comments 回来两个审稿人的意见，加起来很少，但是非常不友好，乱说一通，致命的是说对照组不是标准治疗，我们对照组用的方案在指南里面。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=850, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/29/c68ffa2138c126af3420089371aaee39.jpg, createdBy=b9481711950, createdName=文多多钱多多房多多, createdTime=Mon Sep 27 03:34:50 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887580, encodeId=67bb88e5802b, content=投个image试试水，目前with the editor,看了一下以往发表的文章，应该不符合编辑的口味，据说image拒稿率99%。大家加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=587, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Wed Sep 23 08:27:02 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923533, encodeId=449592353316, content=投了一篇letter不知道with edtor要多少天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Sun Feb 07 20:48:35 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519664, encodeId=68e35196644d, content=投了1篇病例报道，现在Assigned to an Editor，估计希望不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=906, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sat Feb 27 10:15:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114318, encodeId=a6a22114318b9, content=偏重的研究方向：临床研究;随机对照研究 经验分享：投了一篇评论的文章，已经一个多月with editor了，很快文章发表要满14天了，不知道是不是稿件统一处理，希望有好消息！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Mon Feb 13 00:16:54 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122324, encodeId=129721223244b, content=有幸被NEJM一审修回，请问一下修回之后一直显示Administrative Screening，这正常吗？这个状态一般持续多长时间？目前已经10天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07d18126736, createdName=ms3000001187334160, createdTime=Tue Mar 28 20:02:46 CST 2023, time=2023-03-28, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=486910, encodeId=6ccc486910a0, content=近来投了IMAGE IN CLINICAL MEDICINE,不知道结果怎么样，等吧~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1738, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Feb 24 18:02:00 CST 2012, time=2012-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183346, encodeId=65c9218334693, content=23.12.17投稿 picture，with the editor 一月有余, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9f5529296, createdName=ms6000000966266302, createdTime=Tue Jan 23 03:56:44 CST 2024, time=2024-01-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2129787, encodeId=22112129e8779, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床研究;临床医学;随机对照研究 经验分享：国内2023年在NEJM上有可能突破8篇article!2025年十篇以上，以后每年10篇以上，到2030年每年可以达20篇！事实上NEJM每年article也仅100篇多一点。<a href='/topic/show?id=4041126241e' target=_blank style='color:#2F92EE;'>#NEJM#</a><a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=12624, encryptionId=4041126241e, topicName=NEJM), TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed May 03 02:33:50 CST 2023, time=2023-05-03, status=1, ipAttribution=美国)]

2016-02-27 zhihenghuang

投了1篇病例报道，现在Assigned to an Editor，估计希望不大。

906 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1095591, encodeId=1d9510955911a, content=作者可以写中文名么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=541, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055215, encodeId=8c241055215ee, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：临床研究 经验分享：临床研究，2021-7-31投稿；8-1 Administrative Screening，期间格式修改一次耽误几天；8-5 searching for review； 8-8 out for review； 8-25 reject with comments 回来两个审稿人的意见，加起来很少，但是非常不友好，乱说一通，致命的是说对照组不是标准治疗，我们对照组用的方案在指南里面。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=850, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/29/c68ffa2138c126af3420089371aaee39.jpg, createdBy=b9481711950, createdName=文多多钱多多房多多, createdTime=Mon Sep 27 03:34:50 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887580, encodeId=67bb88e5802b, content=投个image试试水，目前with the editor,看了一下以往发表的文章，应该不符合编辑的口味，据说image拒稿率99%。大家加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=587, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Wed Sep 23 08:27:02 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923533, encodeId=449592353316, content=投了一篇letter不知道with edtor要多少天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Sun Feb 07 20:48:35 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519664, encodeId=68e35196644d, content=投了1篇病例报道，现在Assigned to an Editor，估计希望不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=906, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sat Feb 27 10:15:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114318, encodeId=a6a22114318b9, content=偏重的研究方向：临床研究;随机对照研究 经验分享：投了一篇评论的文章，已经一个多月with editor了，很快文章发表要满14天了，不知道是不是稿件统一处理，希望有好消息！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Mon Feb 13 00:16:54 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122324, encodeId=129721223244b, content=有幸被NEJM一审修回，请问一下修回之后一直显示Administrative Screening，这正常吗？这个状态一般持续多长时间？目前已经10天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07d18126736, createdName=ms3000001187334160, createdTime=Tue Mar 28 20:02:46 CST 2023, time=2023-03-28, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=486910, encodeId=6ccc486910a0, content=近来投了IMAGE IN CLINICAL MEDICINE,不知道结果怎么样，等吧~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1738, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Feb 24 18:02:00 CST 2012, time=2012-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183346, encodeId=65c9218334693, content=23.12.17投稿 picture，with the editor 一月有余, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9f5529296, createdName=ms6000000966266302, createdTime=Tue Jan 23 03:56:44 CST 2024, time=2024-01-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2129787, encodeId=22112129e8779, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床研究;临床医学;随机对照研究 经验分享：国内2023年在NEJM上有可能突破8篇article!2025年十篇以上，以后每年10篇以上，到2030年每年可以达20篇！事实上NEJM每年article也仅100篇多一点。<a href='/topic/show?id=4041126241e' target=_blank style='color:#2F92EE;'>#NEJM#</a><a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=12624, encryptionId=4041126241e, topicName=NEJM), TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed May 03 02:33:50 CST 2023, time=2023-05-03, status=1, ipAttribution=美国)]

2023-02-13 采药者来自广东省

偏重的研究方向：临床研究;随机对照研究
经验分享：投了一篇评论的文章，已经一个多月with editor了，很快文章发表要满14天了，不知道是不是稿件统一处理，希望有好消息！

107 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1095591, encodeId=1d9510955911a, content=作者可以写中文名么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=541, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055215, encodeId=8c241055215ee, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：临床研究 经验分享：临床研究，2021-7-31投稿；8-1 Administrative Screening，期间格式修改一次耽误几天；8-5 searching for review； 8-8 out for review； 8-25 reject with comments 回来两个审稿人的意见，加起来很少，但是非常不友好，乱说一通，致命的是说对照组不是标准治疗，我们对照组用的方案在指南里面。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=850, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/29/c68ffa2138c126af3420089371aaee39.jpg, createdBy=b9481711950, createdName=文多多钱多多房多多, createdTime=Mon Sep 27 03:34:50 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887580, encodeId=67bb88e5802b, content=投个image试试水，目前with the editor,看了一下以往发表的文章，应该不符合编辑的口味，据说image拒稿率99%。大家加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=587, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Wed Sep 23 08:27:02 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923533, encodeId=449592353316, content=投了一篇letter不知道with edtor要多少天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Sun Feb 07 20:48:35 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519664, encodeId=68e35196644d, content=投了1篇病例报道，现在Assigned to an Editor，估计希望不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=906, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sat Feb 27 10:15:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114318, encodeId=a6a22114318b9, content=偏重的研究方向：临床研究;随机对照研究 经验分享：投了一篇评论的文章，已经一个多月with editor了，很快文章发表要满14天了，不知道是不是稿件统一处理，希望有好消息！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Mon Feb 13 00:16:54 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122324, encodeId=129721223244b, content=有幸被NEJM一审修回，请问一下修回之后一直显示Administrative Screening，这正常吗？这个状态一般持续多长时间？目前已经10天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07d18126736, createdName=ms3000001187334160, createdTime=Tue Mar 28 20:02:46 CST 2023, time=2023-03-28, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=486910, encodeId=6ccc486910a0, content=近来投了IMAGE IN CLINICAL MEDICINE,不知道结果怎么样，等吧~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1738, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Feb 24 18:02:00 CST 2012, time=2012-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183346, encodeId=65c9218334693, content=23.12.17投稿 picture，with the editor 一月有余, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9f5529296, createdName=ms6000000966266302, createdTime=Tue Jan 23 03:56:44 CST 2024, time=2024-01-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2129787, encodeId=22112129e8779, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床研究;临床医学;随机对照研究 经验分享：国内2023年在NEJM上有可能突破8篇article!2025年十篇以上，以后每年10篇以上，到2030年每年可以达20篇！事实上NEJM每年article也仅100篇多一点。<a href='/topic/show?id=4041126241e' target=_blank style='color:#2F92EE;'>#NEJM#</a><a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=12624, encryptionId=4041126241e, topicName=NEJM), TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed May 03 02:33:50 CST 2023, time=2023-05-03, status=1, ipAttribution=美国)]

2023-03-28 ms3000001187334160 来自辽宁省

有幸被NEJM一审修回，请问一下修回之后一直显示Administrative Screening，这正常吗？这个状态一般持续多长时间？目前已经10天了。

61 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1095591, encodeId=1d9510955911a, content=作者可以写中文名么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=541, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055215, encodeId=8c241055215ee, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：临床研究 经验分享：临床研究，2021-7-31投稿；8-1 Administrative Screening，期间格式修改一次耽误几天；8-5 searching for review； 8-8 out for review； 8-25 reject with comments 回来两个审稿人的意见，加起来很少，但是非常不友好，乱说一通，致命的是说对照组不是标准治疗，我们对照组用的方案在指南里面。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=850, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/29/c68ffa2138c126af3420089371aaee39.jpg, createdBy=b9481711950, createdName=文多多钱多多房多多, createdTime=Mon Sep 27 03:34:50 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887580, encodeId=67bb88e5802b, content=投个image试试水，目前with the editor,看了一下以往发表的文章，应该不符合编辑的口味，据说image拒稿率99%。大家加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=587, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Wed Sep 23 08:27:02 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923533, encodeId=449592353316, content=投了一篇letter不知道with edtor要多少天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Sun Feb 07 20:48:35 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519664, encodeId=68e35196644d, content=投了1篇病例报道，现在Assigned to an Editor，估计希望不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=906, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sat Feb 27 10:15:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114318, encodeId=a6a22114318b9, content=偏重的研究方向：临床研究;随机对照研究 经验分享：投了一篇评论的文章，已经一个多月with editor了，很快文章发表要满14天了，不知道是不是稿件统一处理，希望有好消息！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Mon Feb 13 00:16:54 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122324, encodeId=129721223244b, content=有幸被NEJM一审修回，请问一下修回之后一直显示Administrative Screening，这正常吗？这个状态一般持续多长时间？目前已经10天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07d18126736, createdName=ms3000001187334160, createdTime=Tue Mar 28 20:02:46 CST 2023, time=2023-03-28, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=486910, encodeId=6ccc486910a0, content=近来投了IMAGE IN CLINICAL MEDICINE,不知道结果怎么样，等吧~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1738, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Feb 24 18:02:00 CST 2012, time=2012-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183346, encodeId=65c9218334693, content=23.12.17投稿 picture，with the editor 一月有余, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9f5529296, createdName=ms6000000966266302, createdTime=Tue Jan 23 03:56:44 CST 2024, time=2024-01-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2129787, encodeId=22112129e8779, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床研究;临床医学;随机对照研究 经验分享：国内2023年在NEJM上有可能突破8篇article!2025年十篇以上，以后每年10篇以上，到2030年每年可以达20篇！事实上NEJM每年article也仅100篇多一点。<a href='/topic/show?id=4041126241e' target=_blank style='color:#2F92EE;'>#NEJM#</a><a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=12624, encryptionId=4041126241e, topicName=NEJM), TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed May 03 02:33:50 CST 2023, time=2023-05-03, status=1, ipAttribution=美国)]

2012-02-24 匿名用户

近来投了IMAGE IN CLINICAL MEDICINE,不知道结果怎么样，等吧~~

1738 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1095591, encodeId=1d9510955911a, content=作者可以写中文名么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=541, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055215, encodeId=8c241055215ee, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：临床研究 经验分享：临床研究，2021-7-31投稿；8-1 Administrative Screening，期间格式修改一次耽误几天；8-5 searching for review； 8-8 out for review； 8-25 reject with comments 回来两个审稿人的意见，加起来很少，但是非常不友好，乱说一通，致命的是说对照组不是标准治疗，我们对照组用的方案在指南里面。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=850, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/29/c68ffa2138c126af3420089371aaee39.jpg, createdBy=b9481711950, createdName=文多多钱多多房多多, createdTime=Mon Sep 27 03:34:50 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887580, encodeId=67bb88e5802b, content=投个image试试水，目前with the editor,看了一下以往发表的文章，应该不符合编辑的口味，据说image拒稿率99%。大家加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=587, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Wed Sep 23 08:27:02 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923533, encodeId=449592353316, content=投了一篇letter不知道with edtor要多少天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Sun Feb 07 20:48:35 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519664, encodeId=68e35196644d, content=投了1篇病例报道，现在Assigned to an Editor，估计希望不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=906, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sat Feb 27 10:15:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114318, encodeId=a6a22114318b9, content=偏重的研究方向：临床研究;随机对照研究 经验分享：投了一篇评论的文章，已经一个多月with editor了，很快文章发表要满14天了，不知道是不是稿件统一处理，希望有好消息！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Mon Feb 13 00:16:54 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122324, encodeId=129721223244b, content=有幸被NEJM一审修回，请问一下修回之后一直显示Administrative Screening，这正常吗？这个状态一般持续多长时间？目前已经10天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07d18126736, createdName=ms3000001187334160, createdTime=Tue Mar 28 20:02:46 CST 2023, time=2023-03-28, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=486910, encodeId=6ccc486910a0, content=近来投了IMAGE IN CLINICAL MEDICINE,不知道结果怎么样，等吧~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1738, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Feb 24 18:02:00 CST 2012, time=2012-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183346, encodeId=65c9218334693, content=23.12.17投稿 picture，with the editor 一月有余, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9f5529296, createdName=ms6000000966266302, createdTime=Tue Jan 23 03:56:44 CST 2024, time=2024-01-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2129787, encodeId=22112129e8779, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床研究;临床医学;随机对照研究 经验分享：国内2023年在NEJM上有可能突破8篇article!2025年十篇以上，以后每年10篇以上，到2030年每年可以达20篇！事实上NEJM每年article也仅100篇多一点。<a href='/topic/show?id=4041126241e' target=_blank style='color:#2F92EE;'>#NEJM#</a><a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=12624, encryptionId=4041126241e, topicName=NEJM), TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed May 03 02:33:50 CST 2023, time=2023-05-03, status=1, ipAttribution=美国)]

2024-01-23 ms6000000966266302 来自重庆

23.12.17投稿 picture，with the editor 一月有余

92 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1095591, encodeId=1d9510955911a, content=作者可以写中文名么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=541, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055215, encodeId=8c241055215ee, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：临床研究 经验分享：临床研究，2021-7-31投稿；8-1 Administrative Screening，期间格式修改一次耽误几天；8-5 searching for review； 8-8 out for review； 8-25 reject with comments 回来两个审稿人的意见，加起来很少，但是非常不友好，乱说一通，致命的是说对照组不是标准治疗，我们对照组用的方案在指南里面。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=850, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/29/c68ffa2138c126af3420089371aaee39.jpg, createdBy=b9481711950, createdName=文多多钱多多房多多, createdTime=Mon Sep 27 03:34:50 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887580, encodeId=67bb88e5802b, content=投个image试试水，目前with the editor,看了一下以往发表的文章，应该不符合编辑的口味，据说image拒稿率99%。大家加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=587, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Wed Sep 23 08:27:02 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923533, encodeId=449592353316, content=投了一篇letter不知道with edtor要多少天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd8d2221982, createdName=12103978m50暂无昵称, createdTime=Sun Feb 07 20:48:35 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519664, encodeId=68e35196644d, content=投了1篇病例报道，现在Assigned to an Editor，估计希望不大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=906, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sat Feb 27 10:15:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114318, encodeId=a6a22114318b9, content=偏重的研究方向：临床研究;随机对照研究 经验分享：投了一篇评论的文章，已经一个多月with editor了，很快文章发表要满14天了，不知道是不是稿件统一处理，希望有好消息！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Mon Feb 13 00:16:54 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2122324, encodeId=129721223244b, content=有幸被NEJM一审修回，请问一下修回之后一直显示Administrative Screening，这正常吗？这个状态一般持续多长时间？目前已经10天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07d18126736, createdName=ms3000001187334160, createdTime=Tue Mar 28 20:02:46 CST 2023, time=2023-03-28, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=486910, encodeId=6ccc486910a0, content=近来投了IMAGE IN CLINICAL MEDICINE,不知道结果怎么样，等吧~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1738, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Feb 24 18:02:00 CST 2012, time=2012-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183346, encodeId=65c9218334693, content=23.12.17投稿 picture，with the editor 一月有余, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9f5529296, createdName=ms6000000966266302, createdTime=Tue Jan 23 03:56:44 CST 2024, time=2024-01-23, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2129787, encodeId=22112129e8779, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床研究;临床医学;随机对照研究 经验分享：国内2023年在NEJM上有可能突破8篇article!2025年十篇以上，以后每年10篇以上，到2030年每年可以达20篇！事实上NEJM每年article也仅100篇多一点。<a href='/topic/show?id=4041126241e' target=_blank style='color:#2F92EE;'>#NEJM#</a><a href='/topic/show?id=311b58614a5' target=_blank style='color:#2F92EE;'>#新英格兰医学杂志#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=12624, encryptionId=4041126241e, topicName=NEJM), TopicDto(id=58614, encryptionId=311b58614a5, topicName=新英格兰医学杂志), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed May 03 02:33:50 CST 2023, time=2023-05-03, status=1, ipAttribution=美国)]

2023-05-03 病毒猎手来自美国

审稿速度:2.0 | 投稿命中率:5.0
偏重的研究方向：临床研究;临床医学;随机对照研究
经验分享：国内2023年在NEJM上有可能突破8篇article!2025年十篇以上，以后每年10篇以上，到2030年每年可以达20篇！事实上NEJM每年article也仅100篇多一点。#NEJM##新英格兰医学杂志##期刊论坛#

321 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务